Please use this identifier to cite or link to this item:
|Title:||Theranostics in oncology: What radiologists want to know.|
Fendler, Wolfgang Peter
Morigi, Joshua James
|Citation:||Copyright © 2021. Published by Elsevier B.V.|
Eur J Radiol. 2021 Sep;142:109875. doi: 10.1016/j.ejrad.2021.109875. Epub 2021 Jul 26.
|Abstract:||Combination of radioligand imaging and therapy, so called radiotheranostics, is a novel tool of precision oncology with proven clinical value. In-depth knowledge of functional imaging nuances is critically needed for precise prognostication and guidance of management. Here, we review theranostic applications with up to Phase III type evidence for outcome improvement: Imaging and therapy of neuroendocrine neoplasms (NEN) exploiting high levels of somatostatin receptor (SSTR) expression and radiotheranostics of prostate cancer targeting the prostate specific membrane antigen (PSMA). This narrative review focusses on these two applications and elucidates patient selection and response assessment by radioligand scintigraphy and/or positron emission tomography. Furthermore, we provide a brief outlook on future applications for novel targets outside of NEN and prostate cancer.|
|Click to open Pubmed Article:||https://www.ezpdhcs.nt.gov.au/login?url=https://www.ncbi.nlm.nih.gov/pubmed/34391057|
|Journal title:||European journal of radiology|
|Appears in Collections:||(a) NT Health Research Collection|
Files in This Item:
There are no files associated with this item.
Items in ePublications are protected by copyright, with all rights reserved, unless otherwise indicated.